DrugPatentWatch Database Preview
TYGACIL Drug Profile
» See Plans and Pricing
Which patents cover Tygacil, and when can generic versions of Tygacil launch?
Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-two patent family members in twenty-nine countries.
The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tigecycline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tygacil
A generic version of TYGACIL was approved as tigecycline by SANDOZ INC on May 27th, 2015.
Summary for TYGACIL
International Patents: | 62 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 87 |
Clinical Trials: | 5 |
Patent Applications: | 4,510 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TYGACIL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TYGACIL |
What excipients (inactive ingredients) are in TYGACIL? | TYGACIL excipients list |
DailyMed Link: | TYGACIL at DailyMed |


Recent Clinical Trials for TYGACIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | N/A |
Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
Pharmacology for TYGACIL
Drug Class | Tetracycline-class Antibacterial |
US Patents and Regulatory Information for TYGACIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TYGACIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TYGACIL
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | 211172 | Start Trial |
Denmark | 1858488 | Start Trial |
Spain | 2434944 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TYGACIL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0536515 | SPC/GB06/033 | United Kingdom | Start Trial | PRODUCT NAME: TIGECYCLINE |
0536515 | C00536515/01 | Switzerland | Start Trial | FORMER OWNER: WYETH HOLDINGS CORPORATION, US |
0536515 | CA 2006 00027 | Denmark | Start Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |